stockrow
Friday 6 November 2026
Export PLSE’s income statement to Excel — free account
Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
53.15
3.91
−6.85%
Follow PLSE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(74.45%) | (80.72%) | (78.49%) | (60.67%) | |
| (64.12%) | (69.36%) | (67.90%) | (54.01%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (37.01%) | |
Return on Tangible Assets |
(95.08%) | (119.59%) | (83.58%) | (46.59%) | |
Average Days of Receivables |
165.03 | 77.23 | 37.58 | 72.56 | |
Free Cash Flow per Share |
(0.81) | (0.82) | (0.89) | (3.00) | |
Free Cash Flow |
(54.44) | (55.50) | (61.39) | (216.07) | |
Capital Expenditures |
(0.31) | (0.30) | (0.29) | (152.74) | |
| Other line items | |||||
Cash ROIC |
(33.73%) | (41.23%) | (30.52%) | (98.08%) | |
Accounts Receivable Turnover |
4.11 | 8.99 | 18.66 | 9.58 | |
Accounts Payable Turnover |
0.50 | 0.46 | 0.42 | 0.36 | |
Inventory Turnover |
2.50 | 9.96 | 8.24 | 7.57 | |
Average Days of Payables |
915.63 | 857.67 | 874.52 | 1,006.92 | |
Days of Inventory on Hand |
44.84 | 63.99 | 72.88 | 77.40 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7,379.70% | 6,333.96% | 4,378.57% | 3,838.09% | |
Selling, General and Administrative Expense of Revenue |
5,285.31% | 4,162.94% | 2,629.45% | 2,009.77% | |
Share Based Compensation of Revenue |
3,540.76% | 2,383.83% | 1,474.43% | 1,149.06% | |
Operating CF/Net income |
0.74 | 0.74 | 0.76 | 0.76 | |
Depreciation/Fixed assets |
1.02 | 1.03 | 0.96 | 0.00 | |
Capex/Depreciation |
(0.29) | (0.29) | (0.28) | 0.00 | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF per Share |
(0.80) | (0.81) | (0.88) | (0.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (2.12) | |
Capex to Sales |
0.52 | 0.41 | 0.24 | 102.23 |
Columns are period end dates · fundamentals updated 5 Nov 2026